AzTrials
AzTrials

Cerebellar AtaxiarTMS CANCT07211490

rTMS for Cerebellar Ataxia in Children

A study testing Repetitive Transcranial Magnetic Stimulation in people with Cerebellar Ataxia, run by The University of Hong Kong at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Dysfunction of the cerebellum can result in cerebellar ataxia (CA), typically marked by symptoms such as movement incoordination, gait instability, articulation disorder, oculomotor and swallowing difficulties. Read more about this study

Who is it for?
Ages 4 to 18 years
Conditions the study is for
Cerebellar Ataxia
What is being tested?
Repetitive Transcranial Magnetic Stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
1 siteChina
Study dates
1 Oct 2025to 31 Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Patients aged ≥ 4 years old - 18 years old fulfilling the following criteria: 1) diagnosis of cerebellar ataxia based on clinical history and neurological examination; 2) cerebellar lesion seen by MRI; 3) IQ ≥ 50 to ensure sufficient cognitive capacity for comprehending and adhering to motor training protocols.

Who cannot join

  • Patients will be excluded if they have: 1) Sensory ataxia with etiologies involving the peripheral nerves or posterior columns of the spinal cord, 2) Any contra-indications to rTMS, 3) Severe spasticity (defined as a score of 4 in the Modified Ashworth Scale) and contractures, 4) Uncontrollable epilepsy defined as the occurrence of seizures despite the use of at least one anti-epileptic drug (AED) in adequate dose, 5) History of Botulinum toxin A injection or upper limb casting in previous 6 months, and 6) Cerebellar ataxia resulting from genetic conditions.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Wan Yee Winnie Tso Professor, MBBS contact

+85222554295

wytso@hku.hk

Chai Yin Charlie Fan Miss, OT, BSc contact

+85222554375

charliefan@connect.hku.hk

China1 site
  • The University of Hong Kong

    Hong Kong, Hong Kong

    Wan Yee Winnie Tso Professor, MBBS, +85222554295, wytso@hku.hk

    Chai Yin Charlie Fan Miss, OT, BSc, +85222554375, charliefan@connect.hku.hk

Other trials in China

About this study

Official title: Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Cerebellar Ataxia: A Randomized Controlled Trial

Dysfunction of the cerebellum can result in cerebellar ataxia (CA), typically marked by symptoms such as movement incoordination, gait instability, articulation disorder, oculomotor and swallowing difficulties. Children affected by paediatric cerebellar ataxia (PCA) often suffer from an array of motor symptoms, affecting their quality of life and psychosocial well-being. It was estimated that PCA affects 26/100,000 children worldwide for both genetic and acquired causes. Epidemiological data on PCA, however, are absent in the Hong Kong population.

PCAs comprise a varied group of cerebellar development disorders, marked by impaired balance and motor coordination (e.g., dysmetria and tremor) when performing voluntary movement. Clinical symptoms in children with PCA are related to lesioned localization - focal disorder of the cerebellar vermis leads to truncal instability, head titubation, and nystagmus; while lesioned cerebellar hemispheres results in ataxia gait (wide-staggering gait, tend to fall towards the affected side). These clinical symptoms result in functional difficulties involving balance and walking, reaching, grasping and manipulation, oculomotor and speech domains. Abnormalities of motor excitability have been reported in patients with cerebellar lesions - the motor threshold was found to be raised in the motor cortex contralateral to a hemi-cerebellar lesion.

Read more

With no effective pharmacological treatments available, rehabilitation serves as the primary treatment approach. Even though adaptive learning is affected by cerebellar lesion, motor learning is still possible via exercise interventions. Interventions may include compensatory (educate strategies to compensate for impairment) or restorative approaches (improve functions through training). While exercise interventions have been explored as a potential therapeutic approach for paediatric patients with cerebellar lesions or degeneration, the current evidence lacks robust, high-quality randomized controlled trials (RCTs) to substantiate their efficacy.

Existing evidence shows that cerebellar outputs project to several cortical areas, including the primary motor cortex (M1). CA patients with lesions in structures of the cerebellar efferent pathway exhibit reduced inhibition in the motor cortex. Selective modulation of the efferent pathways may offer an additional means of modulating cortical activity, thus improve motor coordination abilities in CA patients. With the development of non-invasive brain stimulation (NIBS) techniques, more research has been conducted using NIBS as treatment modalities for patients with CA. The most used NIBS techniques include repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS). Repetitive transcranial magnetic stimulation (rTMS) enables to modulate cortical excitability focally in conscious subjects; low-frequency stimulation (e.g., 1 Hz) is known to suppress cortical excitability, while higher frequencies (> 5 Hz) induce facilitation. These changes in excitability occur not only at the site of stimulation but also at other distant interconnected sites of a network. Both the excitatory stimulation and inhibitory stimulation approaches were adopted in existing adult studies. Paediatric patients with cerebellar lesions-caused by stroke, tumour, or genetic conditions-are thought to share the same pathophysiological basis as adults. Using contra-lesional inhibitory rTMS, França et al. demonstrated that the intervention is safe and feasible for adult patients with CA, showing a reduction in ataxic symptoms. Despite promising results in the adult population, it is still unclear whether rTMS can relieve ataxic symptoms and improve motor performance in children with CA.

To date, no studies have been published on the effects of rTMS on improving ataxic symptoms in children with cerebellar ataxia. However, emerging evidence suggests its potential utility. Using rTMS of 1 Hz to stimulate the cerebellar hemisphere ipsilateral to the ataxic side combined with mirror therapy, Cha et al. demonstrated that there was improvement in functional mobility as measured by 6-minute walk test and the timed up and go test. Supporting the feasibility of rTMS in paediatric motor rehabilitation, our pilot RCT (HKWC UW 23-492) found that contra-lesional inhibitory rTMS over M1 combined with motor training is safe and effective in improving motor performance in children with cerebral palsy. Comparative studies in older adults suggest that cerebellar rTMS was more effective than M1 rTMS for motor learning and the consolidation, likely due to the unique role of cerebellum in the integration and processing of multimodal sensory inputs to refine motor planning. These findings highlight the cerebellum as a promising neuromodulatory target for motor rehabilitation, warranting further investigation in paediatric cerebellar ataxia.

Read the detailed description

To address the research gap, our study aims to use low frequency rTMS over the contra-lesional cerebellum in children with cerebellar ataxia. We aim to measure the reduction in ataxic symptoms, the improvement in motor performance functionally as well as using neuroimaging. We hypothesize that low frequency rTMS applied to the contra-lesional cerebellum will lead to reduced ataxic symptoms as measured by ataxia rating scales, improved motor abilities as measured by motor assessment scales, as well as showed improvement in structural as well as functional connectivity. Our study aims to use low frequency stimulation to the contra-lesional cerebellum which will be a safer option as no stimulation will be given to affected brain regions with abnormal brain changes or scarring. This study will be a prospective and randomized controlled study and aims to assess the treatment effect, and the sustainment of the treatment effect, of a 10-day treatment paradigm consisting of: 1) contra-lesional inhibitory rTMS and 2) post-treatment motor training in reducing ataxic symptoms in children with cerebellar ataxia. This study also aims to investigate the underlying neurophysiological mechanisms responsible for the rTMS treatment effect.

The specific hypotheses to be tested include:

  • rTMS followed by motor training will reduce ataxic symptoms as reflected by ataxia rating scales (SARA and ICARS) to a greater extent than training alone in children with cerebellar ataxia.
  • rTMS followed by motor training will lead to better quality of life (QoL) than training alone.
  • rTMS followed by motor training will result in increased cortical plasticity compared to training alone.
  • rTMS followed by motor training will result in brain microstructural changes demonstrated by DKI compared to training alone.
  • rTMS followed by motor training will result in improvement in structural and functional connectivity demonstrated by DKI and resting state fMRI compared to training alone.
Being tested
Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation
Keywords
TMS, Cerebellar ataxia, Children
Medical subject headings
Cerebellar Ataxia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Repetitive Transcranial Magnetic StimulationDevice

    1 Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.

  • Sham Repetitive Transcranial Magnetic StimulationDevice

    Sham Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.

Study groups in NCT07211490
Study groupRoleWhat they receive
Interventional rTMS groupExperimentalThe intervention group will receive 1 Hz rTMS for 15 minutes, followed by 1.5 hours of motor training.
Receives: Device: Repetitive Transcranial Magnetic Stimulation
Sham rTMS groupSham comparatorThe sham group will not receive any Hz of rTMS for 20 minutes, followed by 1.5 hours of motor training.
Receives: Device: Sham Repetitive Transcranial Magnetic Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Scale for Assessment and Rating of Ataxia (SARA)

    an evaluation tool for cerebellar ataxia patients. It consists of the following items: gait, stance, sitting, speech disturbance, finger chase, finger-nose test, fast alternating hand movements, and heel-shin slide.

    Measured: Day 10, 17 of intervention and 2 months post intervention.

  2. The International Cooperative Ataxia Rating Scale (ICARS)

    an assessment scale for severity of cerebellar ataxia. ICARS consists of 19 items divided into four sub-scores: posture and gait disturbances, (limb) kinetic functions, speech disorders, and oculomotor disorders.

    Measured: Day 10, 17 of intervention and 2 months post intervention.

Secondary outcomes (4)
  1. The 10 Metre Walk Test (10MWT)

    an assessment with good reliability and validity to measure locomotor abilities in adults and children.

    Measured: Day 10, 17 of intervention and 2 months post intervention.

  2. The Timed Up and Go Test (TUG)

    a tool originally developed for frail adults/elderly to measure the time taken (in seconds) for an individual to rise from a chair, walk 3 meters, turns, walk back, and sit down. It is also proven that there are good psychometric properties to measure functional mobility in children and adolescents.

    Measured: Day 10, 17 of intervention and 2 months post intervention.

  3. Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2), Subtests 4 and 7

    measure bilateral and upper limb coordination in children and adolescents aged between 4 and 21 years.

    Measured: Day 10, 17 of intervention and 2 months post intervention.

  4. The Pediatric Balance Scale (PBS)

    a measure of balance in school-age children, modified from Berg Balance Scale.

    Measured: Day 10, 17 of intervention and 2 months post intervention.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2025
  2. Study start1 Oct 2025 (estimated)
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07211490
Sponsor's protocol ID
rTMSCAHKU
Acronym
rTMS CA
Status last verified
Oct 2025
First submitted
2 Oct 2025
Last updated
8 Oct 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Repetitive Transcranial Magnetic Stimulation in people with Cerebellar Ataxia, run by The University of Hong Kong at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 8 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Wan Yee Winnie Tso Professor, MBBS (+85222554295, wytso@hku.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Scale for Assessment and Rating of Ataxia (SARA) (time frame: Day 10, 17 of intervention and 2 months post intervention.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in